Top analyst chimes in on bubbling debate about GlaxoSmithKline's future with a clear message: Let your £40B vaccines group go

Geoffrey Porges does not mince words.

The SVB Leerink analyst has a clear message for GlaxoSmithKline investors the day before Emma Walsmley and her top …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Top an­a­lyst chimes in on bub­bling de­bate about Glax­o­SmithK­line's fu­ture with a clear mes­sage: Let your £40B vac­cines group go